Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse

Susan Fletcher, K. Wright, Abbie Adams, Penny Meloni, Russell Johnsen, J.P. Steinhaus, H.M. Moulton, P.L. Iversen, Steve Wilton

    Research output: Contribution to journalArticle

    124 Citations (Scopus)


    Duchenne and Becker muscular dystrophies are allelic disorders arising from mutations in the dystrophin gene. Duchenne muscular dystrophy is characterized by an absence of functional protein, whereas Becker muscular dystrophy, commonly caused by in-frame deletions, shows synthesis of partially functional protein. Anti-sense oligonucleotides can induce specific exon removal during processing of the dystrophin primary transcript, while maintaining or restoring the reading frame, and thereby overcome protein-truncating mutations. The mdx mouse has a non-sense mutation in exon 23 of the dystrophin gene that precludes functional dystrophin production, and this model has been used in the development of treatment strategies for dystrophinopathies. A phosphorodiamidate morpholino oligomer ( PMO) has previously been shown to exclude exon 23 from the dystrophin gene transcript and induce dystrophin expression in the mdx mouse, in vivo and in vitro. In this report, a cell-penetrating peptide ( CPP)- conjugated oligomer targeted to the mouse dystrophin exon 23 donor splice site was administered to mdx mice by intraperitoneal injection. We demonstrate dystrophin expression and near- normal muscle architecture in all muscles examined, except for cardiac muscle. The CPP greatly enhanced uptake of the PMO, resulting in widespread dystrophin expression.
    Original languageEnglish
    Pages (from-to)1587-1592
    JournalMolecular Therapy
    Issue number9
    Publication statusPublished - 2007

    Fingerprint Dive into the research topics of 'Morpholino oligomer-mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse'. Together they form a unique fingerprint.

    Cite this